Treatment of neuromyelitis optica: an evidence based review
Tóm tắt
Neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system characterized by severe optic neuritis and transverse myelitis, usually with a relapsing course. Aquaporin-4 antibody is positive in a high percentage of NMO patients and it is directed against this water channel richly expressed on foot processes of astrocytes. Due to the severity of NMO attacks and the high risk for disability, treatment should be instituted as soon as the diagnosis is confirmed. There is increasing evidence that NMO patients respond differently from patients with multiple sclerosis (MS), and, therefore, treatments for MS may not be suitable for NMO. Acute NMO attacks usually are treated with high dose intravenous corticosteroid pulse and plasmapheresis. Maintenance therapy is also required to avoid further attacks and it is based on low-dose oral corticosteroids and non-specific immunosuppressant drugs, like azathioprine and mycophenolate mofetil. New therapy strategies using monoclonal antibodies like rituximab have been tested in NMO, with positive results in open label studies. However, there is no controlled randomized trial to confirm the safety and efficacy for the drugs currently used in NMO.
Từ khóa
Tài liệu tham khảo
Wingerchuk DM, 1999, The clinical course of neuromyelitis optica (Devic's syndrome), Neurology, 53, 1107, 10.1212/WNL.53.5.1107
Lennon VA, 2004, A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis, Lancet, 364, 2106, 10.1016/S0140-6736(04)17551-X
Pittock SJ, 2006, Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression, Arch Neurol, 63, 964, 10.1001/archneur.63.7.964
Wingerchuk DM, 2006, Revised diagnostic criteria for neuromyelitis optica, Neurology, 66, 1485, 10.1212/01.wnl.0000216139.44259.74
Watanabe S, 2007, Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica, Mult Scler, 13, 128, 10.1177/1352458506071174
Mandler RN, 1998, Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine, Neurology, 51, 1219, 10.1212/WNL.51.4.1219
Watanabe S, 2007, Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis, Mult Scler, 13, 968, 10.1177/1352458507077189
Takahashi T, 2007, Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre, Brain, 130, 1235, 10.1093/brain/awm062
Jarius S, 2008, Antibody to aquaporin-4 in the long-term course of neuromyelitis optica, Brain, 131, 3072, 10.1093/brain/awn240
1993
Guyatt G, 2006, Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force, Chest, 129, 174, 10.1378/chest.129.1.174
Gold R, 2001, Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders, J Neuroimmunol, 117, 1, 10.1016/S0165-5728(01)00330-7
Brusaferri F, 2000, Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials, J Neurol, 247, 435, 10.1007/s004150070172
Nakamura M, 2010, Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica, Graefes Arch Clin Exp Ophthalmol, 248, 1777, 10.1007/s00417-010-1344-7
Clark WF, 1999, Therapeutic plasma exchange: an update from the Canadian Apheresis Group, Ann Intern Med, 131, 453, 10.7326/0003-4819-131-6-199909210-00011
Balogun RA, 2010, Clinical applications of therapeutic apheresis, J Clin Apher, 25, 250, 10.1002/jca.20249
Yoshida H, 2010, Anti-aquaporin-4 antibody-positive optic neuritis treated with double-filtration plasmapheresis, J Ocul Pharmacol, 26, 381, 10.1089/jop.2009.0150
Keller AJ, 1978, Intensive plasma exchange on the cell separator: effects on serum immunoglobulins and complement components, Br J Haematol, 38, 531, 10.1111/j.1365-2141.1978.tb01078.x
Sutton DM, 1989, Complications of plasma exchange, Transfusion, 29, 124, 10.1046/j.1537-2995.1989.29289146829.x
Keegan M, 2002, Plasma exchange for severe attacks of CNS demyelination: predictors of response, Neurology, 58, 143, 10.1212/WNL.58.1.143
Miyamoto K, 2009, Intermittent plasmapheresis prevents recurrence in neuromyelitis optica, Ther Apher Dial, 13, 505, 10.1111/j.1744-9987.2009.00780.x
Cortese I, 2011, Evidence-based guideline update. Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, Neurology, 76, 294, 10.1212/WNL.0b013e318207b1f6
Weinshenker BG, 1999, A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease, Ann Neurol, 46, 878, 10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q
Munemoto M, 2011, Therapeutic efficacy of double filtration plasmapheresis in patients with anti-aquaporin-4 antibody-positive multiple sclerosis, J Clin Neurosci, 18, 478, 10.1016/j.jocn.2010.07.141
Wang KC, 2011, The rescue effect of plasma exchange for neuromyelitis optica, J Clin Neurosci, 18, 43, 10.1016/j.jocn.2010.05.030
Szczepiorkowski ZM, 2010, Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis, J Clin Apher, 25, 83, 10.1002/jca.20240
Carroll W, 2010, Neuromyelitis optica, Curr Treat Options Neurol, 12, 244, 10.1007/s11940-010-0071-z
Higgs JE, 2010, Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications, Pharmacogenomics, 11, 177, 10.2217/pgs.09.155
Bichuetti DB, 2010, Neuromyelitis optica treatment: analysis of 36 patients, Arch Neurol, 67, 1131, 10.1001/archneurol.2010.203
Tanaka Y, 2010, No relapse of neuromyelitis optica during drug-induced B-lymphopenia with hypogammaglobulinemia, Neurology, 75, 1745, 10.1212/WNL.0b013e3181fc2788
Cree BA, 2005, An open label study of the effects of rituximab in neuromyelitis optica, Neurology, 64, 1270, 10.1212/01.WNL.0000159399.81861.D5
Imamura H, 2009, Trial of rituximab in three patients with neuromyelitis optica, Rinsho Shinkeigaku, 49, 457, 10.5692/clinicalneurol.49.457
Capobianco M, 2007, Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease), Neurol Sci, 28, 209, 10.1007/s10072-007-0823-z
Nakashima I, 2011, Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels, J Clin Neurosci, 18, 997, 10.1016/j.jocn.2010.12.011
Jacob A, 2008, Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients, Arch Neurol, 65, 1443, 10.1001/archneur.65.11.noc80069
Bedi GS, 2011, Impact of rituximab on relapse rate and disability in neuromyelitis optica, Mult Scler
Pellkofer HL, 2011, Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab, Neurology, 76, 1310, 10.1212/WNL.0b013e3182152881
Kim S-H, 2011, Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years, Arch Neurol
Goodin DS, 2003, The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, Neurology, 61, 1332, 10.1212/01.WNL.0000095425.84407.39
Weinstock-Guttman B, 2006, Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease), Arch Neurol, 63, 957, 10.1001/archneur.63.7.957
Falcini F, 2006, Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment, Rheumatology, 45, 913, 10.1093/rheumatology/kei263
Jacob A, 2009, Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients, Arch Neurol, 66, 1128, 10.1001/archneurol.2009.175
1991, The Canadian Cooperative Multiple Sclerosis Study Group, Lancet, 337, 441, 10.1016/0140-6736(91)93389-Q
Weiner HL, 1993, Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group, Neurology, 43, 910, 10.1212/WNL.43.5.910
Mok CC, 2008, Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica, J Rheumatol, 35, 172
Birnbaum J, 2008, Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus, Nat Clin Pract Rheumatol, 4, 381, 10.1038/ncprheum0818
Warabi Y, 2007, Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination, J Neurol Sci, 252, 57, 10.1016/j.jns.2006.10.008
Shimizu Y, 2011, Therapeutic efficacy of interferon beta-1b in Japanese patients with optic-spinal multiple sclerosis, Tohoku J Exp Med, 223, 211, 10.1620/tjem.223.211
Uzawa A, 2010, Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis, Eur J Neurol, 17, 672, 10.1111/j.1468-1331.2009.02897.x
Papeix C, 2007, Immunosuppressive therapy is more effective than interferon in neuromyelitis optica, Mult Scler, 13, 256, 10.1177/1352458506070732
Palace J, 2010, Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers, Arch Neurol, 67, 1016, 10.1001/archneurol.2010.188
Hillmen P, 2006, The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria, N Engl J Med, 355, 1233, 10.1056/NEJMoa061648
Bakker J, 2004, Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG), Can J Neurol Sci, 31, 265, 10.1017/S0317167100053932